A. Porter

发表

Rapid isolation of IgNAR variable single-domain antibody fragments from a shark synthetic library.

C. Secombes, C. Shao, A. Porter, 2007, Molecular immunology.

Selection and characterization of naturally occurring single-domain (IgNAR) antibody fragments from immunized sharks by phage display.

Andrew J Porter, Helen Dooley, M. Flajnik, 2003, Molecular immunology.

Separation and concentration of bacteria with immobilized antibody fragments.

W. Harris, P. Molloy, A. Porter, 1995, The Journal of applied bacteriology.

Retention of neutralising activity by recombinant anti-pneumolysin antibody fragments.

W. Harris, A. Porter, M. García, 1998, FEMS immunology and medical microbiology.

Multimeric humanized varicella-zoster virus antibody fragments to gH neutralize virus while monomeric fragments do not.

C. Grose, W. Harris, M. Moss, 2001, The Journal of general virology.

High-Sensitivity Monoclonal Antibodies Specific for Homoserine Lactones Protect Mice from Lethal Pseudomonas aeruginosa Infections

I. Broadbent, A. Porter, K. Charlton, 2013, Applied and Environmental Microbiology.

Non-Alcoholic Steatohepatitis (NASH) – A Review of a Crowded Clinical Landscape, Driven by a Complex Disease

C. Barelle, Julia M. Fraile, J. M. Fraile, 2021, Drug design, development and therapy.

An Anti-hTNF-α Variable New Antigen Receptor Format Demonstrates Superior in vivo Preclinical Efficacy to Humira® in a Transgenic Mouse Autoimmune Polyarthritis Disease Model

Obinna C Ubah, C. Barelle, A. Porter, 2019, Front. Immunol..

Anti-DLL4 VNAR targeted nanoparticles for targeting of both tumour and tumour associated vasculature.

C. Barelle, C. Scott, M. Greene, 2020, Nanoscale.

Using a recombinant single chain antibody for targeting liver myofibroblasts with anti-fibrogenic therapeutics

K. Wallace, C. Barelle, M. Wright, 2010 .

Targeting liver myofibroblasts: a novel approach in anti-fibrogenic therapy

K. Wallace, C. Barelle, M. Wright, 2008, Hepatology international.

Uveitis Therapy With Shark Variable Novel Antigen Receptor Domains Targeting Tumor Necrosis Factor Alpha or Inducible T-Cell Costimulatory Ligand

Obinna C Ubah, Kathryn L. Pepple, R. V. Van Gelder, 2019, Translational vision science & technology.

Reduced toxicity of expression, in Escherichia coli, of antipollutant antibody fragments and their use as sensitive diagnostic molecules

W. Harris, A. Porter, G. Strachan, 1999, Journal of applied microbiology.

Binding characteristics of anti-atrazine monoclonal antibodies and their fragments synthesised in bacteria and plants.

S. D. Grant, W. Harris, A. Porter, 1998, Biosensors & bioelectronics.

Cloning, expression and characterization of a single‐chain antibody specific for the herbicide atrazine

S. D. Grant, W. Harris, A. Porter, 1996 .

Expression and characterisation of single-chain antibody fragments produced in transgenic plants against the organic herbicides atrazine and paraquat.

C. Newell, M. Longstaff, W. Hamilton, 1998, Biochimica et biophysica acta.

Mechanisms of SARS-CoV-2 neutralization by shark variable new antigen receptors elucidated through X-ray crystallography

Obinna C Ubah, A. LeBeau, Eric W. Lake, 2021, Nature Communications.

VNARs: An Ancient and Unique Repertoire of Molecules That Deliver Small, Soluble, Stable and High Affinity Binders of Proteins

C. Barelle, A. Porter, 2015 .

Anti-mesotrione single chain antibody fragments derived using either phage display or via hybridoma technology: selection, characterization and stabilization

D. C. Holt, A. Porter, G. Strachan, 2003 .

Repertoire as Revealed from a Bacteriophage Analysis of the Diversity of a Sheep Antibody

W. Harris, A. Porter, K. Charlton, 2000 .

Production of a functional single chain antibody attached to the surface of a plant virus

S. Santa Cruz, I. Roberts, T. Wilson, 1998, FEBS letters.

Generation of a monoclonal human single chain antibody fragment to hepatic stellate cells--a potential mechanism for targeting liver anti-fibrotic therapeutics.

M. Wright, A. Porter, G. Strachan, 2005, Journal of hepatology.

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties.

Obinna C Ubah, Magdalena J Buschhaus, C. Barelle, 2020, Methods in molecular biology.

Rapid selection of anti-hapten antibodies isolated from synthetic and semi-synthetic antibody phage display libraries expressed in Escherichia coli.

L. Lawton, A. Porter, G. Strachan, 2002, FEMS microbiology letters.

Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.

K. Wallace, I. Broadbent, E. Durward, 2008, Journal of hepatology.

Isolation of anti-hapten specific antibody fragments from combinatorial libraries.

A. Porter, K. Charlton, 2002, Methods in molecular biology.

Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model

C. Munro, D. MacCallum, L. Walker, 2021, bioRxiv.

In Vitro ELISA and Cell-Based Assays Confirm the Low Immunogenicity of VNAR Therapeutic Constructs in a Mouse Model of Human RA: An Encouraging Milestone to Further Clinical Drug Development

Obinna C Ubah, C. Barelle, A. Porter, 2020, Journal of immunology research.

Atrazine analysis using an amperometric immunosensor based on single-chain antibody fragments and regeneration-free multi-calibrant measurement

Anthony J. Killard, Malcolm R. Smyth, A. Killard, 2003 .

Host-targeting protein 1 (SpHtp1) from the oomycete Saprolegnia parasitica translocates specifically into fish cells in a tyrosine-O-sulphate–dependent manner

S. Whisson, P. van West, Stephan Wawra, 2012, Proceedings of the National Academy of Sciences.

Oriented attachment of VNAR proteins, via site-selective modification, on PLGA–PEG nanoparticles enhances nanoconjugate performance† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c9cc02655j

Daniel A. Richards, V. Chudasama, C. Barelle, 2019, Chemical communications.

Analysis of the Diversity of a Sheep Antibody Repertoire as Revealed from a Bacteriophage Display Library1

W. Harris, A. Porter, K. Charlton, 2000, The Journal of Immunology.

Monoclonal Human Antibodies That Recognise the Exposed N and C Terminal Regions of the Often-Overlooked SARS-CoV-2 ORF3a Transmembrane Protein

C. Munro, A. Porter, Soumya Palliyil, 2021, Viruses.

Shark variable new antigen receptor biologics – a novel technology platform for therapeutic drug development

C. Barelle, A. Porter, J. Steven, 2014, Expert opinion on biological therapy.

Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction

D. Cullen, Mohammed M. Al Qaraghuli, A. Porter, 2015, BMC Biotechnology.

Stabilization of antibody fragments in adverse environments

S. D. Grant, W. Harris, H. Dooley, 1998, Biotechnology and applied biochemistry.

Immunomethods for Detecting a Broad Range of Polychlorinated Biphenyls

W. Harris, H. Dooley, A. Porter, 1998 .

Therapeutic Potential of Shark Anti-ICOSL VNAR Domains is Exemplified in a Murine Model of Autoimmune Non-Infectious Uveitis

C. Barelle, A. Porter, J. Steven, 2017, Front. Immunol..

Detection and quantification of microcystins (cyanobacterial hepatotoxins) with recombinant antibody fragments isolated from a naïve human phage display library.

L. Lawton, A. Porter, J McElhiney, 2000, FEMS microbiology letters.

In Vitro Maturation of a Humanized Shark VNAR Domain to Improve Its Biophysical Properties to Facilitate Clinical Development

Obinna C Ubah, C. Barelle, A. Porter, 2017, Front. Immunol..

Monoclonal Antibodies Targeting Surface-Exposed Epitopes of Candida albicans Cell Wall Proteins Confer In Vivo Protection in an Infection Model

C. Munro, D. MacCallum, L. Walker, 2022, Antimicrobial agents and chemotherapy.

Identification of a truncated ratp28-related protein expressed in kidney.

M. Wright, A. Porter, N. Ingram, 2004, Biochemical and biophysical research communications.

Next-generation flexible formats of VNAR domains expand the drug platform's utility and developability.

John Steven, Obinna C Ubah, Magdalena J Buschhaus, 2018, Biochemical Society transactions.

Bacterial surface display of an anti‐pollutant antibody fragment

A. Porter, P. Drew, J. Dhillon, 1999, Letters in applied microbiology.

The isolation of super-sensitive anti-hapten antibodies from combinatorial antibody libraries derived from sheep.

W J Harris, W. Harris, A. Porter, 2001, Biosensors & bioelectronics.

Isolation of highly selective IgNAR variable single-domains against a human therapeutic Fc scaffold and their application as tailor-made bioprocessing reagents.

Magdalena J Buschhaus, Stefan Becker, C. Barelle, 2019, Protein engineering, design & selection : PEDS.

Expression of monovalent and bivalent antibody fragments in Escherichia coli.

S. D. Grant, W. Harris, A. Porter, 1995, Journal of hematotherapy.

Toxicity of the bacterial luciferase substrate, n‐decyl aldehyde, to Saccharomyces cerevisiae and Caenorhabditis elegans

K. Killham, G. Paton, R. Hollis, 2001, FEBS letters.

Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury.

K. Wallace, I. Broadbent, E. Durward, 2008, Journal of hepatology.